Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen
Desvenlafaxine for the Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen: a Randomized, Double-blind, Placebo-controlled Study
Sponsor: Korea Cancer Center Hospital
Terminated
Difficulty in Recruiting Research Participants
Other terminated trials from Korea Cancer Center Hospital
- Uterine Cervical Neoplasms · Phase PHASE1/PHASE2 · Apr 2012
- Ovarian Neoplasms · Phase PHASE2 · Oct 2010
More terminations from Korea Cancer Center Hospital
Listed as NCT02819921, this PHASE4 trial focuses on Breast Neoplasms and Hot Flashes and remains terminated or withdrawn. Sponsored by Korea Cancer Center Hospital, it has been updated 11 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Oct 2019 — Jan 2021 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
▶ Show 6 earlier versions
-
Jun 2018 — Oct 2019 [monthly]
Recruiting PHASE4
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Dec 2017 — May 2018 [monthly]
Not Yet Recruiting PHASE4
-
Aug 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE4
-
May 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Korea Cancer Center Hospital
- Pfizer
- Seoul National University Bundang Hospital
- Seoul National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .